Metoclopramide Medical Valley (Metoclopramide Hydrochloride Bp)

The drug blocks dopamine D2 receptors in the chemoreceptor trigger zone of the brain and in the gastrointestinal tract, which reduces the sensation of nausea. It also antagonizes 5‑HT3 receptors and stimulates 5‑HT4 receptors, actions that increase lower‑esophageal sphincter tone and promote faster gastric emptying.

The appropriate dose is determined by the prescribing clinician based on the patient’s condition, age, renal function and other individual factors. Dosage regimens may differ for acute nausea, chronic gastroparesis or other indications, and should always follow the prescriber’s instructions.

The pregnancy category for Metoclopramide is listed as unknown, and safety data are limited. It should only be used during pregnancy or while breastfeeding if the potential benefit outweighs any possible risk, and after a thorough discussion with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoclopramide differs from agents such as domperidone by acting centrally on dopamine receptors as well as peripherally on serotonin receptors, giving it both anti‑emetic and pro‑kinetic effects. Domperidone primarily blocks peripheral dopamine receptors and has fewer central nervous system side effects, but it may be less effective for certain types of nausea.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain stability.

Metoclopramide Medical Valley is taken orally, usually with a glass of water. It can be taken with or without food, although some clinicians advise taking it 30 minutes before meals to optimise its pro‑kinetic effect. Follow the prescriber’s specific instructions regarding timing and frequency.

The most concerning adverse effects include extrapyramidal symptoms such as dystonia or akathisia, the potential for tardive dyskinesia with long‑term use, and rare occurrences of neuroleptic malignant syndrome. Patients should be monitored closely for any involuntary movements, muscle rigidity or fever and report them immediately.

Metoclopramide is contraindicated in individuals with known hypersensitivity to the drug, those with pheochromocytoma, seizure disorders, or a history of severe extrapyramidal reactions. Caution is also advised for patients with gastrointestinal obstruction, perforation or severe renal impairment.